ArticlePharmaceutics2022

Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer.

Thomas Rodier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.